eMedicine Specialties > Pediatrics: General Medicine > Allergy & Immunology
Myeloperoxidase Deficiency: Follow-up
Updated: Oct 29, 2008
Follow-up
Inpatient & Outpatient Medications
- See Medical Care.
Prognosis
- A group from Europe who studied patients with complete myeloperoxidase (MPO) deficiency found that about half had infectious complications, while the other half were asymptomatic. Infectious complications were life threatening in about 10% of cases.
- Others have reported severe infections occurring in fewer than 5% of patients with MPO deficiency (this frequency may be based on the inclusion of both complete and partial deficiencies). Infections generally occur only in patients who have concomitant diabetes mellitus.
Miscellaneous
Medicolegal Pitfalls
- Because most patients with myeloperoxidase (MPO) deficiency do not have serious or life-threatening infections, failure to diagnose MPO deficiency may have no adverse consequences. Indeed, because at least half of patients with MPO deficiency are asymptomatic, most cases are undiagnosed. However, failure to make the diagnosis in a patient with MPO deficiency with recurrent serious infections could lead to medicolegal consequences.
- If an infectious disease occurs in a patient with MPO deficiency who also has diabetes mellitus, it is usually a fungal infection (particularly candidal species such as C albicans or C tropicalis). Patients without diabetes mellitus rarely have problems. Consider the possibility of MPO deficiency in a case of invasive fungal infection in a patient with no known predisposing immune defects (eg, chemotherapy, corticosteroid treatment) or in a patient with concomitant diabetes mellitus.
More on Myeloperoxidase Deficiency |
| Overview: Myeloperoxidase Deficiency |
| Differential Diagnoses & Workup: Myeloperoxidase Deficiency |
| Treatment & Medication: Myeloperoxidase Deficiency |
Follow-up: Myeloperoxidase Deficiency |
| References |
| « Previous Page |
References
Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood. Aug 2008;112:935-945. [Medline].
Stefanescu A, Braun S, Ndrepepa G, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J. Feb 2008;155:356-360. [Medline].
Kutter D, Devaquet P, Vanderstocken G, et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol. 2000;104(1):10-5. [Medline].
Nauseef WM. Insights into myeloperoxidase biosynthesis from its inherited deficiency. J Mol Med. Sep 1998;76(10):661-8. [Medline].
Nauseef WM. Lessons from MPO deficiency about functionally important structural features. Jpn J Infect Dis. Oct 2004;57(5):S4-5. [Medline].
Lanza F. Clinical manifestation of myeloperoxidase deficiency. J Mol Med. Sep 1998;76(10):676-81. [Medline].
Kutter D. Prevalence of myeloperoxidase deficiency: population studies using Bayer-Technicon automated hematology. J Mol Med. Sep 1998;76(10):669-75. [Medline].
Nunoi H, Kohi F, Kajiwara H, Suzuki K. Prevalence of inherited myeloperoxidase deficiency in Japan. Microbiol Immunol. 2003;47(7):527-31. [Medline].
Taioli E, Benhamou S, Bouchardy C, et al. Myeloperoxidase G463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. Feb 2007;9:67-73. [Medline].
Nauseef WM, Cogley M, and McCormick S. Effect of the R569W missense mutation on the bio-synthesis of myeloperoxidase. J Biol Chem. Apr 1996;271:9546-9549. [Medline].
Ohashi YY, Kameoka Y, Persad AS, et al. Novel missense mutation found in a Japanese patient with myeloperoxidase deficiency. Gene. Mar 3 2004;327(2):195-200. [Medline].
Persad AS, Kameoka Y, Kanda S, Niho Y, Suzuki K. Arginine to cysteine mutation (R499C) found in a Japanese patient with complete myeloperoxidase deficiency. Gene Expr. 2006;13(2):67-71. [Medline].
Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. Oct 2007;219:88-102. [Medline].
Mauch L, Lun A, O'Gorman MRG, et al. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. Mar 2007;53:890-896. [Medline].
Boxer LA, Blackwood RA. Leukocyte disorders: quantitative and qualitative disorders of the neutrophil, part 2. Pediatr Rev. Feb 1996;17(2):47-50. [Medline].
DeLeo FR, Goedken M, McCormick SJ, Nauseef WM. A novel form of hereditary myeloperoxidase deficiency linked to endoplasmic reticulum/proteasome degradation. J Clin Invest. Jun 15 1998;101(12):2900-9. [Medline]. [Full Text].
Marchetti C, Patriarca P, Solero GP, Baralle FE, Romano M. Genetic characterization of myeloperoxidase deficiency in Italy. Hum Mutat. May 2004;23(5):496-505. [Medline].
Marchetti C, Patriarca P, Solero GP, Baralle FE, Romano M. Genetic studies on myeloperoxidase deficiency in Italy. Jpn J Infect Dis. Oct 2004;57(5):S10-2. [Medline].
Milla C, Yang S, Cornfield DN, et al. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol. Oct 2004;287(4):L706-14. [Medline]. [Full Text].
Molin L, Stendahl O. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand. 1979;206(6):451-7. [Medline].
Nauseef WM. Myeloperoxidase deficiency. Hematol Pathol. 1990;4(4):165-78. [Medline].
Nauseef WM. Myeloperoxidase deficiency. Hematol Oncol Clin North Am. Mar 1988;2(1):135-58. [Medline].
Nauseef WM. Quality control in the endoplasmic reticulum: lessons from hereditary myeloperoxidase deficiency. J Lab Clin Med. Sep 1999;134(3):215-21. [Medline].
Nauseef WM, Cogley M, Bock S, Petrides PE. Pattern of inheritance in hereditary myeloperoxidase deficiency associated with the R569W missense mutation. J Leukoc Biol. Feb 1998;63(2):264-9. [Medline].
Petrides PE. Molecular genetics of peroxidase deficiency. J Mol Med. Sep 1998;76(10):688-98. [Medline].
Petrides PE, Nauseef WM. Molecular and clinical aspects of neutrophil peroxidase deficiency: multidisciplinary approaches on an international scale. J Mol Med. Sep 1998;76(10):659-60. [Medline].
Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest. Jul 1978;62(1):214-20. [Medline]. [Full Text].
Further Reading
Keywords
myeloperoxidase deficiency, MPO, MPO deficiency, lead toxicity, iron deficiency, diabetes mellitus, renal transplantation, acute myeloid leukemia, AML, chronic myeloid leukemia, CML, polycythemia vera, Hodgkin disease, Hodgkin's disease, refractory megaloblastic anemia, aplastic anemia, myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, Staphylococcus aureus, Serratia, Escherichia coli, Candida albicans, Candida krusei, Candida stellatoidea, Candida tropicalis, atherosclerosis
Follow-up: Myeloperoxidase Deficiency